Lotus Eye Hospital and Institute
- Market cap
- ₹ 234 Cr.
- P/E
- 305x
- P/B
- 3.83x
- 52-week range
- 97.59 – 147
- ROE
- 0%
- ROCE
- 1.2%
- Dividend yield
- 0%
- Debt / equity
- 0.26
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Lotus Eye Hospital and Institute Limited is an India-based company, which is engaged in the business of healthcare activities. The Company is engaged in the field of ophthalmology (eye) and its related operations. It resolves a range of eye problems, such as refractive, cataract, cornea infections, ocular prosthesis, orbit and oculoplasty, glaucoma, keratoconus, computer vision syndrome, neuro ophthalmology, retinal disease/diabetic eye care, UVEA and ocular inflammation, zyoptix-ultimate, and binocular vision. The Company provides various treatments, suchas ReLEx SMILE, Touchfree Laser, Lasik Eye Surgery, Epi-LASIK, Intralase, Supracor, Robotic Femto Laser Cataract Surgery (LRCS), Phacoemulsification, Paediatric Eye Care and Squint Surgery, and Micro Incision Cataract Surgery (MICS). The Company operates in various locations, such as Sitra, Coimbatore; RS Puram, Coimbatore; Salem; Tirupur; Mettupalayam; Kochi; Mulanthuruthy; Saravanampatty, and Karur.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Lotus Eye Hospital and Institute against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)305 against a typical 48.9: pricier than most peers (1st = cheapest).40th of 40
- Sales growth+26.2% against a typical +21.1% from a year earlier.14th of 34
- Profit growth+13% against a typical +13% from a year earlier.16th of 31
- Share price, 3 months−8.3% against a typical −10.9%.14th of 34
- Size₹ 233.6 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).23rd of 36
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 10 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 26 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 17 Mar 2026 | Voluntary Delisting | To consider the proposal for voluntary delisting of the Company's equity shares from NSE |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 12 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 12 | 11 | 13 | 13 | 12 | 12 | 14 | 13 | 14 | 14 | 17 |
| Expenses | 11 | 10 | 10 | 11 | 12 | 11 | 12 | 12 | 12 | 13 | 13 | 14 |
| Operating Profit | 2 | 2 | 1 | 2 | 1 | 1 | −0 | 1 | 1 | 1 | 0 | 3 |
| OPM % | 14.2% | 13.1% | 7% | 12.9% | 8.9% | 6.5% | −1.5% | 11% | 5.9% | 4.9% | 3.5% | 17.3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | −1 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 1 | 1 | 0 | 1 | 0 | −0 | 1 | 1 | 0 | −0 | −0 | 1 |
| Tax % | 28.6% | 26.7% | −200% | 28.2% | 9.1% | −44.2% | 70.2% | 24.7% | −71.4% | −29.7% | −33.3% | 39.6% |
| Net Profit | 1 | 1 | 0 | 1 | 0 | −0 | 0 | 1 | 0 | −0 | −0 | 1 |
| EPS in Rs | 0.41 | 0.32 | 0.01 | 0.3 | 0.05 | −0.12 | 0.12 | 0.26 | 0.06 | −0.13 | −0.15 | 0.29 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 6%
- 5 Years
- 11%
- 3 Years
- 5%
- TTM
- 14%
- 10 Years
- −1%
- 5 Years
- −44%
- 3 Years
- −73%
- TTM
- −75%
- 10 Years
- 22%
- 5 Years
- 22%
- 3 Years
- 12%
- TTM
- —
- 10 Years
- 3%
- 5 Years
- 4%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Lotus Eye Hospital and Institute | ₹ 109.12 | ₹ 234 Cr. | 305x | 3.8x | 0% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Ramanujam Reghunathan
- Chief Financial Officer
- Prathish S
- Compliance Officer, Company Secretary
- Sangeetha K. Sundaramoorthy
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.